SGLT-2 Inhibitors for Patients with Heart Failure: What Have We Learned Recently?
Purpose of Review In this review, we discuss the mechanisms of action of sodium-glucose cotransporter-2 inhibitors (SGLT-2i) and the purported protective effects for mitigating heart failure (HF)-related outcomes. Recent Findings Major randomized clinical trials have demonstrated the cardiovascular...
Gespeichert in:
| Veröffentlicht in: | Current atherosclerosis reports 2022-08, Vol.24 (8), p.627-634 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 634 |
|---|---|
| container_issue | 8 |
| container_start_page | 627 |
| container_title | Current atherosclerosis reports |
| container_volume | 24 |
| creator | Al Rifai, Mahmoud Newby, L. Kristin Nair, Ajith P. Misra, Arunima Rogers, Joseph G. Fedson, Savitri Virani, Salim S. |
| description | Purpose of Review
In this review, we discuss the mechanisms of action of sodium-glucose cotransporter-2 inhibitors (SGLT-2i) and the purported protective effects for mitigating heart failure (HF)-related outcomes.
Recent Findings
Major randomized clinical trials have demonstrated the cardiovascular safety and efficacy of SGLT-2i among patients without known HF and those with established HF with reduced ejection fraction or preserved ejection fraction (HFrEF and HFpEF respectively). Recent HF guidelines have incorporated SGLT-2i in HF treatment algorithms.
Summary
SGLT-2i have emerged as a novel treatment for both prevention of HF and reduction of cardiovascular morbidity and mortality among patients with existing HFrEF or HFpEF. |
| doi_str_mv | 10.1007/s11883-022-01038-2 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2672704887</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2672704887</sourcerecordid><originalsourceid>FETCH-LOGICAL-c347t-49f6451773fed90b8498a23a219d07d1dda35893bce185fde35f8216cf902753</originalsourceid><addsrcrecordid>eNp9kMtOwzAQRS0EoqXwAyyQl2wMtieJHTYIVfQhVeJVqUvLSSY0VZoUOwH170lpYclqRppzrzSHkEvBbwTn6tYLoTUwLiXjgoNm8oj0RQgBi2Qgj3e7BAaaBz1y5v2Kc8l1JE5JD8IoBA7QJy9v49mcSTqtlkVSNLXzNK8dfbZNgVXj6VfRLOkErWvoyBZl6_COLpa2oRP7iXSBdNbdKszoK6ZdoNzen5OT3JYeLw5zQOajx_lwwmZP4-nwYcZSCFTDgjiPglAoBTlmMU90EGsrwUoRZ1xlIssshDqGJEWhwzxDCHMtRZTmMZcqhAG53tduXP3Rom_MuvAplqWtsG69kZGSigdaqw6VezR1tfcOc7Nxxdq6rRHc7EyavUnTmTQ_Jo3sQleH_jZZY_YX-VXXAbAHfHeq3tGZVd26qnv5v9pvJIB8HA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2672704887</pqid></control><display><type>article</type><title>SGLT-2 Inhibitors for Patients with Heart Failure: What Have We Learned Recently?</title><source>Springer Nature - Complete Springer Journals</source><creator>Al Rifai, Mahmoud ; Newby, L. Kristin ; Nair, Ajith P. ; Misra, Arunima ; Rogers, Joseph G. ; Fedson, Savitri ; Virani, Salim S.</creator><creatorcontrib>Al Rifai, Mahmoud ; Newby, L. Kristin ; Nair, Ajith P. ; Misra, Arunima ; Rogers, Joseph G. ; Fedson, Savitri ; Virani, Salim S.</creatorcontrib><description>Purpose of Review
In this review, we discuss the mechanisms of action of sodium-glucose cotransporter-2 inhibitors (SGLT-2i) and the purported protective effects for mitigating heart failure (HF)-related outcomes.
Recent Findings
Major randomized clinical trials have demonstrated the cardiovascular safety and efficacy of SGLT-2i among patients without known HF and those with established HF with reduced ejection fraction or preserved ejection fraction (HFrEF and HFpEF respectively). Recent HF guidelines have incorporated SGLT-2i in HF treatment algorithms.
Summary
SGLT-2i have emerged as a novel treatment for both prevention of HF and reduction of cardiovascular morbidity and mortality among patients with existing HFrEF or HFpEF.</description><identifier>ISSN: 1523-3804</identifier><identifier>EISSN: 1534-6242</identifier><identifier>DOI: 10.1007/s11883-022-01038-2</identifier><identifier>PMID: 35653033</identifier><language>eng</language><publisher>New York: Springer US</publisher><subject>Angiology ; Cardiology ; Coronary Heart Disease (S. Virani and M. Al Rifai ; Medicine ; Medicine & Public Health ; Section Editors ; Topical Collection on Coronary Heart Disease</subject><ispartof>Current atherosclerosis reports, 2022-08, Vol.24 (8), p.627-634</ispartof><rights>This is a U.S. government work and not under copyright protection in the U.S.; foreign copyright protection may apply 2022</rights><rights>2022. This is a U.S. government work and not under copyright protection in the U.S.; foreign copyright protection may apply.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c347t-49f6451773fed90b8498a23a219d07d1dda35893bce185fde35f8216cf902753</citedby><cites>FETCH-LOGICAL-c347t-49f6451773fed90b8498a23a219d07d1dda35893bce185fde35f8216cf902753</cites><orcidid>0000-0001-9541-6954</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s11883-022-01038-2$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s11883-022-01038-2$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,777,781,27905,27906,41469,42538,51300</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35653033$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Al Rifai, Mahmoud</creatorcontrib><creatorcontrib>Newby, L. Kristin</creatorcontrib><creatorcontrib>Nair, Ajith P.</creatorcontrib><creatorcontrib>Misra, Arunima</creatorcontrib><creatorcontrib>Rogers, Joseph G.</creatorcontrib><creatorcontrib>Fedson, Savitri</creatorcontrib><creatorcontrib>Virani, Salim S.</creatorcontrib><title>SGLT-2 Inhibitors for Patients with Heart Failure: What Have We Learned Recently?</title><title>Current atherosclerosis reports</title><addtitle>Curr Atheroscler Rep</addtitle><addtitle>Curr Atheroscler Rep</addtitle><description>Purpose of Review
In this review, we discuss the mechanisms of action of sodium-glucose cotransporter-2 inhibitors (SGLT-2i) and the purported protective effects for mitigating heart failure (HF)-related outcomes.
Recent Findings
Major randomized clinical trials have demonstrated the cardiovascular safety and efficacy of SGLT-2i among patients without known HF and those with established HF with reduced ejection fraction or preserved ejection fraction (HFrEF and HFpEF respectively). Recent HF guidelines have incorporated SGLT-2i in HF treatment algorithms.
Summary
SGLT-2i have emerged as a novel treatment for both prevention of HF and reduction of cardiovascular morbidity and mortality among patients with existing HFrEF or HFpEF.</description><subject>Angiology</subject><subject>Cardiology</subject><subject>Coronary Heart Disease (S. Virani and M. Al Rifai</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Section Editors</subject><subject>Topical Collection on Coronary Heart Disease</subject><issn>1523-3804</issn><issn>1534-6242</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNp9kMtOwzAQRS0EoqXwAyyQl2wMtieJHTYIVfQhVeJVqUvLSSY0VZoUOwH170lpYclqRppzrzSHkEvBbwTn6tYLoTUwLiXjgoNm8oj0RQgBi2Qgj3e7BAaaBz1y5v2Kc8l1JE5JD8IoBA7QJy9v49mcSTqtlkVSNLXzNK8dfbZNgVXj6VfRLOkErWvoyBZl6_COLpa2oRP7iXSBdNbdKszoK6ZdoNzen5OT3JYeLw5zQOajx_lwwmZP4-nwYcZSCFTDgjiPglAoBTlmMU90EGsrwUoRZ1xlIssshDqGJEWhwzxDCHMtRZTmMZcqhAG53tduXP3Rom_MuvAplqWtsG69kZGSigdaqw6VezR1tfcOc7Nxxdq6rRHc7EyavUnTmTQ_Jo3sQleH_jZZY_YX-VXXAbAHfHeq3tGZVd26qnv5v9pvJIB8HA</recordid><startdate>20220801</startdate><enddate>20220801</enddate><creator>Al Rifai, Mahmoud</creator><creator>Newby, L. Kristin</creator><creator>Nair, Ajith P.</creator><creator>Misra, Arunima</creator><creator>Rogers, Joseph G.</creator><creator>Fedson, Savitri</creator><creator>Virani, Salim S.</creator><general>Springer US</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-9541-6954</orcidid></search><sort><creationdate>20220801</creationdate><title>SGLT-2 Inhibitors for Patients with Heart Failure: What Have We Learned Recently?</title><author>Al Rifai, Mahmoud ; Newby, L. Kristin ; Nair, Ajith P. ; Misra, Arunima ; Rogers, Joseph G. ; Fedson, Savitri ; Virani, Salim S.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c347t-49f6451773fed90b8498a23a219d07d1dda35893bce185fde35f8216cf902753</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Angiology</topic><topic>Cardiology</topic><topic>Coronary Heart Disease (S. Virani and M. Al Rifai</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Section Editors</topic><topic>Topical Collection on Coronary Heart Disease</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Al Rifai, Mahmoud</creatorcontrib><creatorcontrib>Newby, L. Kristin</creatorcontrib><creatorcontrib>Nair, Ajith P.</creatorcontrib><creatorcontrib>Misra, Arunima</creatorcontrib><creatorcontrib>Rogers, Joseph G.</creatorcontrib><creatorcontrib>Fedson, Savitri</creatorcontrib><creatorcontrib>Virani, Salim S.</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Current atherosclerosis reports</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Al Rifai, Mahmoud</au><au>Newby, L. Kristin</au><au>Nair, Ajith P.</au><au>Misra, Arunima</au><au>Rogers, Joseph G.</au><au>Fedson, Savitri</au><au>Virani, Salim S.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>SGLT-2 Inhibitors for Patients with Heart Failure: What Have We Learned Recently?</atitle><jtitle>Current atherosclerosis reports</jtitle><stitle>Curr Atheroscler Rep</stitle><addtitle>Curr Atheroscler Rep</addtitle><date>2022-08-01</date><risdate>2022</risdate><volume>24</volume><issue>8</issue><spage>627</spage><epage>634</epage><pages>627-634</pages><issn>1523-3804</issn><eissn>1534-6242</eissn><abstract>Purpose of Review
In this review, we discuss the mechanisms of action of sodium-glucose cotransporter-2 inhibitors (SGLT-2i) and the purported protective effects for mitigating heart failure (HF)-related outcomes.
Recent Findings
Major randomized clinical trials have demonstrated the cardiovascular safety and efficacy of SGLT-2i among patients without known HF and those with established HF with reduced ejection fraction or preserved ejection fraction (HFrEF and HFpEF respectively). Recent HF guidelines have incorporated SGLT-2i in HF treatment algorithms.
Summary
SGLT-2i have emerged as a novel treatment for both prevention of HF and reduction of cardiovascular morbidity and mortality among patients with existing HFrEF or HFpEF.</abstract><cop>New York</cop><pub>Springer US</pub><pmid>35653033</pmid><doi>10.1007/s11883-022-01038-2</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0001-9541-6954</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1523-3804 |
| ispartof | Current atherosclerosis reports, 2022-08, Vol.24 (8), p.627-634 |
| issn | 1523-3804 1534-6242 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2672704887 |
| source | Springer Nature - Complete Springer Journals |
| subjects | Angiology Cardiology Coronary Heart Disease (S. Virani and M. Al Rifai Medicine Medicine & Public Health Section Editors Topical Collection on Coronary Heart Disease |
| title | SGLT-2 Inhibitors for Patients with Heart Failure: What Have We Learned Recently? |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-20T12%3A45%3A18IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=SGLT-2%20Inhibitors%20for%20Patients%20with%20Heart%20Failure:%20What%20Have%20We%20Learned%20Recently?&rft.jtitle=Current%20atherosclerosis%20reports&rft.au=Al%20Rifai,%20Mahmoud&rft.date=2022-08-01&rft.volume=24&rft.issue=8&rft.spage=627&rft.epage=634&rft.pages=627-634&rft.issn=1523-3804&rft.eissn=1534-6242&rft_id=info:doi/10.1007/s11883-022-01038-2&rft_dat=%3Cproquest_cross%3E2672704887%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2672704887&rft_id=info:pmid/35653033&rfr_iscdi=true |